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Background
Autologous neutralizing antibody responses against HIV-
1 have been shown to emerge a number of months after
primary infection. It is not known why neutralizing anti-
bodies against HIV-1 are relatively slow to appear. We use
the SIV/rhesus macaque model to characterize the kinetics
of autologous neutralizing antibody responses and enve-
lope sequence evolution in 4 rhesus monkeys infected
intrarectally with SIVmac251.
Methods
We assessed the presence of autologous neutralizing anti-
bodies at 3, 5, 8, 16, and 22 months post-infection using
pseudovirion-based, luciferase-reporter gene neutralizing
antibody assays. We then analyzed full-length SIV env
sequences at selected time points. The capacity of sera to
neutralize variant viruses was also determined.
Results
Sera from 4 SIVmac251-infected monkeys neutralized the
inoculating virus at 8 months, but not at 5 months after
infection. These sera did not neutralize autologous or het-
erologous SIV variants that were cloned at later time
points, indicating that variant viruses had mutated to
escape neutralization. After escape, these circulating viral
variants became the predominant viral quasispecies in all
animals. The majority of genotypic changes clustered in
variable loops 1/2 (V1/2) and 4 (V4) of env. These
changes resulted in the deletion of neutralizing epitopes
and shifts in potential N-linked glycosylation sites.
Conclusion
We show that SIVmac251, a strain of SIV that is relatively
resistant to antibody-mediated neutralization, induces
potent autologous neutralizing antibodies by 8 months
post-infection. The late emergence of neutralizing anti-
bodies appears to be related to the inherent properties of
primate lentiviruses, since the kinetics of SIVmac251 neu-
tralization mirrors what has been reported with HIV-1.
The evolution of SIV env implicates V1/2 and V4 region as
the determinants of antibody neutralization. The develop-
ment of these antibodies resulted in complete replace-
ment of neutralization-sensitive virus by resistant viruses,
providing evidence that humoral immune responses exert
potent selection pressure on SIV despite their late emer-
gence.
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